Anti-HLA-G chimeric antigen receptor and application thereof

By developing chimeric antigen receptors (CARs) that specifically bind HLA-G and introducing immune cells, the problem of difficulty in treatment after cancer metastasis is solved, efficient killing of overexpressing HLA-G cancer cells is achieved, and treatment is significantly improved Effect.

CN118946585AInactive Publication Date: 2024-11-12HK INNO N CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030276.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-25
Filing Date
2023-03-24
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing cancer treatments are not effective after cancer metastasis, especially because the expression of HLA-G allows cancer cells to escape the immune system, resulting in increased treatment difficulty.

Method used

A chimeric antigen receptor (CAR) specifically binding to human leukocyte antigen-G (HLA-G) was developed to enhance its cancers expressing HLA-G by introducing it into T cells and natural killer (NK) cells. Cell killing ability. The CAR includes an antigen-binding domain, a transmembrane domain and an intracellular signaling domain that specifically binds to HLA-G, which can activate immune cells and induce apoptosis of cancer cells.

Benefits of technology

Immune cells expressing anti-HLA-G CAR show high anti-cancer activity, able to specifically recognize and kill cancer cells overexpressing HLA-G, significantly improving the therapeutic effect on a variety of cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946585A_ABST
    Figure CN118946585A_ABST
Patent Text Reader

Abstract

The present invention relates to: a chimeric antigen receptor comprising an antigen binding site that specifically binds to HLA-G, which is an immune checkpoint; an immune cell into which the receptor is introduced; and their use. According to the present invention, the immune cell can effectively remove cancer cells in which an immune checkpoint is expressed, so that even activation of endogenous immune cells that have been inhibited by the immune checkpoint can be expected, and thus can be effectively used as an immunotherapeutic method for various cancer diseases related to HLA-G.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a chimeric antigen receptor (CAR) comprising an antigen binding domain that specifically binds to human leukocyte antigen-G (HLA-G), an immune cell into which the receptor is introduced, and uses thereof. Background Art

[0002] Methods for treating cancer have undergone continuous development and change, and methods such as surgery, chemotherapy, and radiotherapy are still used today. However, most of these existing cancer treatment methods are only effective in the early stages when the cancer has not yet metastasized, and there is a problem that when metastasis has already occurred, there is a high probability of recurrence even after surgery. Therefore, research on methods for treating cancer using immune responses has been conducted recently.

[0003] Among them, people are increasingly interested in cell therapy methods that use immune cells to enhance immune responses or genetically modify immune cells and then inject them back into the patient. In the latter method, chimeric antigen receptor (CAR)-T cells are being widely studied. CAR-T cells are cells that give T cells targeting functions by introducing artificially designed CAR molecules into T cells, and because CAR molecules show specificity for specific tumor antigens, they can only eliminate tumor cells.

[0004] In general, CAR includes an extracellular antigen binding domain, a transmembrane (TM) domain, and an intracellular signaling domain. The extracellular antigen binding domain may include a single-chain variable fragment (scFv) targeting an identified tumor antigen.

[0005] Meanwhile, human major histocompatibility antigens class I and G, also known as human leukocyte antigen-G (HLA-G), are immune checkpoint factors that inhibit the activation and division of T cells, natural killer (NK) cells, and cytotoxic T cells. Known immune cell receptors for HLA-G include Ig-like transcript 2 (ILT2), ILT4, killer cell immunoglobulin-like receptor two Ig domains and long cytoplasmic tail 4 (KIR2DL4), etc., and all of these receptors have an immunoreceptor tyrosine-based inhibitory (ITIM) motif. When HLA-G binds to the receptor, the signaling pathway that inhibits immune cells is activated by this motif.

[0006] Although the expression of HLA-G is limited to normal cells, it has been reported that HLA-G is expressed in many types of cancer cells (Lin A, Yan WH. Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy. Mol. Med. 21 (1), 782-791 (2015)). In addition, it has been reported that the expression level of HLA-G in cancer cells of many cancer patients is related to the stage of cancer, and it has also been reported that the survival rate of patients expressing HLA-G is low (Ye, Sr., Yang, H., Li, K. et al. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod. Pathol. 20, 375-383 (2007)). Summary of the invention

[0007] Technical issues

[0008] The present inventors have conducted a lot of research work to develop chimeric antigen receptors (CARs) that can effectively treat diseases related to human leukocyte antigen-G (HLA-G) expression and immune cells comprising the chimeric antigen receptors. Therefore, anti-HLA-G CARs that specifically bind to HLA-G and T cells and NK cells expressing the CARs are produced. In addition, the present inventors have confirmed that T cells and NK cells exhibit high anticancer activity against cell lines expressing HLA-G, thereby completing the present invention.

[0009] Therefore, an object of the present invention is to provide an anti-HLA-G CAR and an immune cell expressing the receptor.

[0010] Another object of the present invention is to provide a nucleic acid comprising nucleotides encoding anti-HLA-G CAR and a vector comprising the nucleic acid.

[0011] Still another object of the present invention is to provide a pharmaceutical composition comprising immune cells and a pharmaceutically acceptable carrier.

[0012] Technical Solution

[0013] To achieve the above objectives, one aspect of the present invention provides an anti-HLA-G CAR, which includes an antigen binding domain that specifically binds to HLA-G; a TM domain; and an intracellular signaling domain.

[0014] In one embodiment of the present invention, the antigen binding domain that specifically binds to HLA-G may comprise a sequence selected from the following:

[0015] (a) a heavy chain variable region comprising a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 31, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 32, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 33; and

[0016] a light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 34, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 35, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 36;

[0017] (b) a heavy chain variable region comprising a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 37, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 38, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 39; and

[0018] a light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO:40, a light chain CDR2 having the amino acid sequence of SEQ ID NO:41, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:42; or

[0019] (c) a heavy chain variable region comprising a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 43, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 44, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 45; and

[0020] A light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO:46, a light chain CDR2 having the amino acid sequence of SEQ ID NO:47, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:48.

[0021] As used herein, the term "chimeric antigen receptor (CAR)" refers to a receptor protein formed by combining a receptor site of an immune cell (e.g., T cell) with a recognition site of a specific antigen expressed on the surface of a cancer cell, so that the immune cell can recognize a specific protein. These receptors have a chimeric nature because they combine an antigen binding site that can recognize an antigen expressed by a tumor and a signaling site that can activate T cells.

[0022] In one embodiment of the present invention, CAR includes an antigen binding domain, a TM domain, and an intracellular signaling domain. The antigen binding domain recognizes the HLA-G of the target cell and can be an antibody or an antibody fragment. In addition, the antigen binding fragment can be a single-chain variable fragment (scFv), but is not limited thereto.

[0023] In one embodiment of the present invention, the antigen binding site may comprise a heavy chain variable region sequence and a light chain variable region sequence, and the two sequences may be connected by a linker comprising the amino acid sequence of SEQ ID NO: 24. Therefore, the antigen binding site may be in the form of scFv.

[0024] As used herein, the term "heavy chain" refers to a full-length heavy chain (which comprises a variable region domain VH comprising sufficient variable region amino acid sequence to confer specificity to an antigen) and three constant region domains CH1, CH2 and CH3, and fragments thereof.

[0025] As used herein, the term "light chain" refers to a full-length light chain (which comprises a variable region domain VL comprising sufficient variable region amino acid sequence to confer specificity to an antigen) and a constant region domain CL and fragments thereof.

[0026] In one embodiment of the present invention, the antigen binding domain may comprise the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, and specifically, may be composed of an amino acid sequence having 80% or greater, preferably 90% or greater, more preferably 95% or greater, and most preferably 99% or greater sequence homology with the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4 or SEQ IDNO:6.

[0027] Additionally, the antigen binding domain may comprise:

[0028] (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:25 or an amino acid sequence having 80% or greater sequence homology to SEQ ID NO:25, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:26 or an amino acid sequence having 80% or greater sequence homology to SEQ ID NO:26;

[0029] (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:27, or an amino acid sequence having 80% or greater sequence homology to SEQ ID NO:27, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:28, or an amino acid sequence having 80% or greater sequence homology to SEQ ID NO:28; or

[0030] (c) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:29 or an amino acid sequence having 80% or greater sequence homology to SEQ ID NO:29, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:30 or an amino acid sequence having 80% or greater sequence homology to SEQ ID NO:30.

[0031] CAR may also include a leader sequence (LS). LS refers to a sequence that allows CAR to translocate to the cell membrane to be expressed and exposed on the cell surface.

[0032] In one embodiment of the present invention, the LS may be an LS derived from cluster of differentiation 8α (CD8α), human immunoglobulin heavy chain, or human granulocyte-macrophage colony stimulating factor (hGM-CSF) receptor α-chain, and specifically, may be a CD8α-derived LS.

[0033] The CD8α-derived LS may comprise the amino acid sequence of SEQ ID NO:8, and specifically, may consist of an amino acid sequence having 80% or greater, preferably 90% or greater, more preferably 95% or greater, and most preferably 99% or greater sequence homology with the amino acid sequence of SEQ ID NO:8.

[0034] In the CAR of the present invention, the antigen binding domain that specifically binds to HLA-G can be connected to the TM domain by a hinge. The hinge can be derived from the following group consisting of: a hinge of CD8α, a hinge of IgG1, a hinge of IgG4, a hinge of IgD, an IgG1CH3, an extracellular domain of CD28, or a combination thereof, and in particular, can be derived from CD8α. The hinge derived from CD8α may include an amino acid sequence of SEQ ID NO: 10, and in particular, may be composed of an amino acid sequence having 80% or more, preferably 90% or more, more preferably 95% or more, and most preferably 99% or more sequence homology to the amino acid sequence of SEQ ID NO: 10.

[0035] In the CAR of the present invention, the TM domain is a domain that connects the antigen binding domain and the intracellular signaling domain via the cell membrane. The TM domain can be a TM domain of a protein selected from the group consisting of: CD8α, T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD99, CD134, CD137 and CD154 alpha (α), beta (β) or zeta (ζ), and specifically, it can be a TM domain of CD8α.

[0036] The TM domain of CD8α may comprise the amino acid sequence of SEQ ID NO: 12, and specifically, may be composed of an amino acid sequence having 80% or greater, preferably 90% or greater, more preferably 95% or greater, and most preferably 99% or greater sequence homology with the amino acid sequence of SEQ ID NO: 12.

[0037] In the CAR of the present invention, the intracellular signaling domain (ICD) is a site that generates a signal that activates the immune response of immune cells when the antigen binding site of the extracellular domain binds to HLA-G.

[0038] The intracellular signaling domain can be derived from a protein selected from the group consisting of: CD3ζ, Fcγ receptor (FcγR), inducible T cell co-stimulator (ICOS; CD278), 4-1BB (CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9)), OX40 (CD134), CD27, CD28, interleukin-2 receptor β (IL-2Rβ), IL-15R-α, CD40, myeloid differentiation primary response 88 (MyD88), DNAX activating protein 10 (DAP10), DAP12, major histocompatibility complex (MHC) class I molecules, tumor necrosis factor (TNF) receptor protein white, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte activation molecule (SLAM) proteins, activated NK cell receptors, B and T lymphocyte attenuation factor (BTLA), toll-like receptors (TLR), CD2, CD7, CD30, CD99, CDS, intercellular adhesion molecule-1 (ICAM-1), B7-H3 (CD276), glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR), B cell activating factor (BAFF) receptor (BAFFR), lymphotoxin-β receptor interacting cytokine (LIGHT), herpes virus entry mediator (HVEM) (LIGHT receptor (LIGHTR)), killer cell immunoglobulin-like receptor two Ig domains and short cytoplasmic tail 2 (KIRDS2), signaling lymphocyte activation molecule (SLAM) family member 7 (SLAMF7), NKp80 (killer cell lectin-like receptor subfamily F member 1 (KLRF1)), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL2Rγ, IL7Rα, integrin subunit α4 (ITGA4), very late antigen-1 (VLA1), CD49a, IA4, CD49D, integrin subunit α6 (ITGA6), VLA-6, CD49f, integrin subunit αD (ITGAD), CD11d, integrin subunit αE (ITGAE), CD103, integrin subunit αL (ITGAL), CD11a, lymphocyte function-associated antigen-1 (LFA-1; CD11a / CD18), integrin subunit αM (ITGAM), CD11b, integrin subunit αX (ITGAX), CD11c, integrin β-1 (ITGB1), CD29, integrin β-2 (ITGB2), CD18, integrin β-7 (ITGB7), natural killer group 2 member D (NKG2D; killer cell lectin-like receptor K1 (KLRK1)), natural killer group 2 member C (NKG2C;(Killer cell lectin-like receptor C2 (KLRC2)), tumor necrosis factor receptor 2 (TNFR2), TNF-related activation-inducing cytokine (TRANCE; nuclear factor κB receptor activator ligand (RANKL)), DNAX accessory molecule-1 (DNAM1; CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Touch), carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), cytotoxic and regulatory T cell molecule (CRTAM), Ly9 (CD229), CD160 (BY55), P-selectin glycoprotein ligand 1 (PSGL1; CD162), CD100 (Semaphorin 4D (SEMA4) D)), CD69, SLAMF6 (NK-TB antigen (NTB-A)), Ly108, SLAMF1 (CD150, IPO-3), B lymphocyte activation regulator and enhancer (BLAME; SLAMF8), lymphotoxin-β receptor (LTBR), T cell activation adaptor (LAT), glutamic acid decarboxylase (GADS), 76-kDa leukocyte phosphoprotein containing Src sequence homology region 2 (SH2) domain (SLP-76), phosphoprotein associated with glycosphingolipid-rich microdomain / C-terminal Src kinase (Csk) binding protein (PAG / Cbp), CD19a and CD83 specific ligands, and specifically, CD3ζ derived intracellular signaling domain. ;

[0039] The CD3ζ-derived intracellular signaling domain may comprise the amino acid sequence of SEQ ID NO: 16, and specifically, may consist of an amino acid sequence having 80% or greater, preferably 90% or greater, more preferably 95% or greater, and most preferably 99% or greater sequence homology with the amino acid sequence of SEQ ID NO: 16.

[0040] In addition, the intracellular signaling domain may also include a co-stimulatory domain to further activate immune cells and increase their activity. The co-stimulatory domain may be derived from a protein selected from the group consisting of: OX40, CD2, CD27, CD28, CD99, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278) and 4-1BB (CD137), and specifically, may be derived from 4-1BB.

[0041] The 4-1BB-derived costimulatory domain may comprise the amino acid sequence of SEQ ID NO: 14, and specifically, may consist of an amino acid sequence having 80% or greater, preferably 90% or greater, more preferably 95% or greater, and most preferably 99% or greater sequence homology to the amino acid sequence of SEQ ID NO: 14.

[0042] In one embodiment of the present invention, CAR may comprise the amino acid sequence of SEQ ID NO: 18, SEQ ID NO: 20 or SEQ ID NO: 22, and specifically, may be composed of an amino acid sequence having 80% or greater, preferably 90% or greater, more preferably 95% or greater, and most preferably 99% or greater sequence homology with the amino acid sequence of SEQ ID NO: 18, SEQ ID NO: 20 or SEQ ID NO: 22.

[0043] Another aspect of the invention is an isolated nucleic acid comprising a nucleotide sequence encoding an anti-HLA-G CAR.

[0044] As used herein, the term "nucleic acid" has a comprehensive meaning, including DNA and RNA molecules, and nucleotides as the basic units of nucleic acid molecules, including not only natural nucleotides, but also analogs in which the sugar or base moiety is modified (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews (1990) 90: 543-584). The sequence of the nucleic acid molecule encoding the anti-HLA-G CAR of the present invention may be modified, and the modification includes the addition, deletion, or non-conservative or conservative substitution of nucleotides.

[0045] In one embodiment of the present invention, the isolated nucleic acid comprising a nucleotide sequence encoding an anti-HLA-G CAR comprises a nucleotide sequence encoding an antigen binding site that specifically binds to HLA-G. The nucleotide sequence encoding the antigen binding site may comprise a nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5, and specifically, may consist of a nucleotide sequence having a sequence homology of 80% or more, preferably 90% or more, more preferably 95% or more, and most preferably 99% or more with the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5.

[0046] In one embodiment of the present invention, the isolated nucleic acid comprising a nucleotide sequence encoding an anti-HLA-G CAR may comprise a nucleotide sequence of SEQ ID NO: 17, SEQ ID NO: 19 or SEQ ID NO: 21, and specifically, may consist of a nucleotide sequence having a sequence homology of 80% or greater, preferably 90% or greater, more preferably 95% or greater, and most preferably 99% or greater to the nucleotide sequence of SEQ ID NO: 17, SEQ ID NO: 19 or SEQ ID NO: 21.

[0047] Still another aspect of the present invention is a recombinant vector comprising a nucleic acid molecule.

[0048] The vector used in the present invention may be a variety of vectors known in the art, and depending on the type of host cell in which the antigen receptor is to be produced, expression regulatory sequences such as promoters, terminators, enhancers, sequences for membrane targeting or secretion, etc. can be appropriately selected and combined in various ways according to the purpose.

[0049] Methods for transducing the vector of the present invention into cells and expressing it are well known in the art. The vector can be easily introduced into a host cell, such as a mammal, a bacterium, a yeast or an insect cell, by methods known in the art. For example, the vector can be delivered to the host cell by physical, chemical or biological means. Physical means include calcium phosphate precipitation, lipid transfection, particle bombardment, microinjection, electroporation, etc. Chemical means include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles and liposomes. In addition, biological means include the use of the above-mentioned DNA or RNA vectors, such as slow viruses and retroviruses.

[0050] The vector of the present invention includes plasmid vectors, cosmid vectors, phage vectors and viral vectors, but is not limited thereto. In addition to expression regulatory factors such as promoters, operators, start codons, stop codons, polyadenylation signals and enhancers, suitable vectors may also contain signal sequences or leader sequences for membrane targeting or secretion and may be produced in various ways according to the purpose.

[0051] In one embodiment of the present invention, a lentiviral vector is used. In one embodiment of the present invention, the vector further comprises a promoter. The promoter may be, for example, an elongation factor 1 (EF-1) promoter, but is not limited thereto.

[0052] The present invention also provides an immune cell expressing the above-mentioned anti-HLA-G CAR on the cell surface.

[0053] In the present invention, the immune cell may be selected from the group consisting of natural killer cells, T cells, natural killer T cells, B cells, macrophages, dendritic cells, natural killer dendritic cells, mast cells, and precursor cells thereof.

[0054] The anti-HLA-G CAR can be introduced into immune cells via the above-mentioned vector, and a standard technique suitable for the host cells can be selected as the introduction method, as known in the art.

[0055] In one embodiment of the present invention, CAR-expressing T cells and NK cells are produced by transfecting T cells and NK cells with a recombinant vector containing a polynucleotide capable of encoding an anti-HLA-G CAR. Specifically, the anti-HLA-G CAR coding sequence contained in the recombinant vector is transcribed into mRNA, and the anti-HLA-G CAR polypeptide is translated from the mRNA and displayed on the surface of T cells and NK cells. If necessary, T cells and NK cells transfected with the recombinant vector can be cultured.

[0056] Immune cells expressing anti-HLA-G CAR can recognize HLA-G as an antigen and bind specifically to HLA-G. After binding, it can induce immune cell activation and induce tumor-specific cell apoptosis through the intracellular signaling domain.

[0057] Therefore, another aspect of the present invention provides a pharmaceutical composition for preventing or treating cancer, comprising immune cells and a pharmaceutically acceptable carrier.

[0058] In the present invention, the pharmaceutical composition can be used to treat cancers that overexpress HLA-G, but is not limited thereto. The cancer can be selected from the group consisting of pancreatic cancer, breast cancer, ovarian cancer, glioma, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, liver cancer, lung cancer, colon cancer, nasopharyngeal cancer, oral cancer, thyroid cancer, prostate cancer, kidney cancer, gallbladder cancer, bile duct cancer, blood cancer, melanoma, etc.

[0059] The blood cancer may be acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), multiple myeloma (MM), or lymphoma.

[0060] As used herein, the term "prevention" refers to any action to inhibit or delay the progression of a disease by administering the composition of the present invention, and "treatment" refers to inhibiting, alleviating or eliminating the development of a disease.

[0061] The pharmaceutical composition of the present invention may also include a pharmaceutically acceptable carrier, which is a carrier commonly used in preparation and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talcum powder, magnesium stearate and mineral oil, but is not limited thereto. In addition to the above ingredients, the composition for preventing or treating cancer of the present invention may also include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. Suitable pharmaceutically acceptable carriers and preparations are described in detail in the document [Remington's Pharmaceutical Sciences (19th edition, 1995)].

[0062] In addition, the pharmaceutical composition of the present invention can be administered by oral administration, infusion, intravenous injection, intramuscular injection, subcutaneous injection, intraperitoneal injection, rectal administration, topical administration, intranasal injection, etc., but the administration method is not limited thereto. In the case of oral administration, since the protein or peptide is digested, the oral composition can be formulated to coat the active agent or protect it from decomposition in the stomach, and the composition of the present invention can be administered by any means that allows the active substance to move to the target cell.

[0063] The suitable dosage of the pharmaceutical composition of the present invention depends on factors such as formulation method, administration method, patient's age, weight, sex and pathological condition, food, administration time, administration route, excretion rate and reaction sensitivity, and the doctor of ordinary skills can easily determine the effective dosage for the desired treatment or prevention and prescribe. The composition may preferably include CAR-expressing immune cells according to the present invention, and its amount is 1 to 10 times the number of tumor cells (e.g., pancreatic cancer, breast cancer, ovarian cancer or glioma) in the subject to be treated, but is not limited thereto.

[0064] According to one embodiment of the present invention, the pharmaceutical composition of the present invention may contain 1 to 10 times the number of immune cells (e.g., T cells or natural killer cells) in a single dose as the number of tumor cells (e.g., pancreatic cancer cells, breast cancer cells, ovarian cancer cells or glioma cells) in the subject to be treated.

[0065] As used herein, the term "pharmaceutically effective amount" refers to an amount sufficient for treating, preventing and diagnosing a disease.

[0066] The pharmaceutical composition of the present invention can be prepared in unit dosage form, or can be prepared by placing it in a multidose container, by using a pharmaceutically acceptable carrier and / or excipient according to the method that can be easily implemented by a person skilled in the art to which the present invention belongs. At this time, the preparation can be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or it can be in the form of an extract, powder, suppository, granule, tablet or capsule, and can also contain a dispersant or stabilizer.

[0067] The compositions of the present invention may be administered as a sole therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents.

[0068] Another aspect of the present invention is a method for diagnosing, preventing or treating a disease (e.g., cancer) associated with HLA-G overexpression, the method comprising administering an anti-HLA-G CAR of the present invention, or an immune cell expressing CAR, or a pharmaceutical composition to a subject, such as a human or non-human mammal, in a pharmaceutically effective amount. The present invention also provides a method for diagnosing a disease (e.g., cancer) associated with HLA-G overexpression, the method comprising administering an anti-HLA-G CAR of the present invention or an immune cell expressing CAR to an individual in need, such as a human or non-human mammal.

[0069] As used herein, the term "subject" refers to any animal that has developed or is likely to develop a disease associated with HLA-G overexpression, including humans, monkeys, cows, horses, sheep, pigs, chickens, turkeys, quail, cats, dogs, mice, rats, rabbits, or guinea pigs.

[0070] Beneficial Effects

[0071] Since the CAR according to the present invention has excellent specificity and affinity for HLA-G, immune cells expressing anti-HLA-G CAR have excellent cytotoxicity to cancer cells and can be used to treat various cancers associated with overexpression of HLA-G. BRIEF DESCRIPTION OF THE DRAWINGS

[0072] Figures 1a to 1c It is a diagram illustrating the structures of the HLA-G CAR (antibody fragment 1 CAR), HLA-G CAR (antibody fragment 2 CAR), and HLA-G CAR (antibody fragment 3 CAR) constructs of the present invention.

[0073] Figures 2a to 2c It is a diagram illustrating the structures of the pLV-EF1A-HLA-G CAR (antibody fragment 1 CAR), pLV-EF1A-HLA-G CAR (antibody fragment 2 CAR), and pLV-EF1A-HLA-G CAR (antibody fragment 3 CAR) plasmids of the present invention.

[0074] Figure 3 It is a diagram illustrating the structure of the pLV-EF1A-B2M-IRES-HLA-G-CMV-EGFP-T2A-PuroR plasmid of the present invention.

[0075] Figure 4 This is a graph confirming the HLA-G expression rate in the SK-OV-3-HLA-G and MDA-MB-231-HLA-G overexpressing cell lines of the present invention.

[0076] Figures 5a to 5c This is a graph confirming the CAR expression rate on the surface of the anti-HLA-G CAR-expressing T cells of the present invention.

[0077] Figures 6a to 6c Graphs illustrating the anti-cancer efficacy of the anti-HLA-G CAR-expressing T cells of the present invention against SK-OV-3-HLA-G, MDA-MB-231-HLA-G, SK-OV-3, and MDA-MB-231 cell lines.

[0078] Figure 7 is a graph illustrating the activity of anti-HLA-G CAR-expressing T cells of the present invention against SK-OV-3-HLA-G, MDA-MB-231-HLA-G, SK-OV-3 and MDA-MB-231 cell lines, as demonstrated by the secretion of interferon gamma.

[0079] Figure 8 This is a graph illustrating the CAR expression rate on the surface of T cells expressing anti-HLA-G CAR cultured with IL-2 and IL-7 / IL-15 cytokines in the present invention.

[0080] Fig. 9 is a graph illustrating the anti-cancer efficacy of T cells expressing anti-HLA-G CAR cultured with IL-2 and IL-7 / IL-15 cytokines in the present invention against SK-OV-3-HLA-G and SK-OV-3 cell lines.

[0081] Fig.10 is a graph illustrating the viability of anti-HLA-G CAR expressing T cells of the present invention cultured with IL-2 and IL-7 / IL-15 cytokines against SK-OV-3-HLA-G and SK-OV-3 cell lines, as demonstrated by the secretion of interferon gamma.

[0082] Fig.11 It is a graph illustrating the expression rates of CD3 and CD56 in NK cells expressing the anti-HLA-G CAR of the present invention.

[0083] Fig.12It is a graph illustrating the CAR expression rate on the surface of NK cells expressing the anti-HLA-G CAR of the present invention.

[0084] Fig.13 It is a graph illustrating the anti-cancer efficacy of the anti-HLA-G CAR-expressing NK cells of the present invention against SK-OV-3-HLA-G and SK-OV-3 cell lines. DETAILED DESCRIPTION

[0085] Hereinafter, the present invention will be described in more detail by way of examples. These examples are intended only to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention should not be construed as being limited by these examples.

[0086] Example 1: Cell lines and culture

[0087] Human ovarian cancer cell line SK-OV-3 and human triple negative breast cancer cell line MDA-MB-231 were provided by Korea Cell Line Bank (Korea). SK-OV-3 and MDA-MB-231 were cultured in Roswell Park Memorial Institute (RPMI 1640; Gibco, USA) medium containing 10% fetal bovine serum (FBS) (Gibco, USA) and 1% antibiotic-antimycotic (Gibco, USA).

[0088] Example 2: Generation and culture of HLA-G overexpressing cell lines

[0089] 2-1. Production of lentivirus expressing B2M-HLA-G-EGFP-PuroR gene

[0090] Plasmid DNA was used to generate lentivirus for delivery of the B2M-HLA-G-EGFP-PuroR gene. TransIT-293 transfection reagent (Mirus Bio LLC, USA) was used for transfection according to the manufacturer's protocol. Lenti-X TM 5×10 of 293T cell line (Clontech, USA) 6 Cells were plated in 100-mm dishes and on the next day, the cells were transfected with the pLV-EF1A-B2M-IRES-HLA-G-CMV-EGFP-T2A-PuroR lentiviral vector ( Figure 3), gag-pol expression vector and vesicular stomatitis virus-G (VSV-G) envelope expression vector transfected cells. After about 72 hours of cell culture, all cell supernatants were harvested. The supernatant was filtered through a 0.45 μm filter (Millipore, USA) to remove cell debris, and the filtrate containing B2M-HLA-G-EGFP-PuroR lentivirus was frozen and stored at -80°C until use.

[0091] 2-2. Generation and culture of SK-OV-3 and MDA-MB-231 cell lines expressing B2M-HLA-G-EGFP-PuroR gene

[0092] One day before the experiment, 1x10 cells of SK-OV-3 and MDA-MB-231 cells were cultured. 6 Individual cells were inoculated in 100mm culture dishes, and for each culture dish, 3mL of previously prepared B2M-HLA-G-EGFP-PuroR lentivirus was mixed with 7mL of fresh culture medium and added to the culture dish. In addition, polybrene was added to the culture medium at a concentration of 8μg / mL. Then, 24 hours later, the culture medium was replaced with a fresh culture medium containing 2μg / mL puromycin (Sigma-Aldrich, the United States). When the selection by puromycin was carried out to a certain extent, the cells were subcultured in 96-well plates at a concentration of 0.5 cells / well to separate HLA-G overexpressing cells into single cells. After the final selection was completed, puromycin was added to the culture medium at a concentration of 0.5μg / mL. By observing under a fluorescence microscope, several holes with high enhanced green fluorescent protein (EGFP) fluorescence signals were selected, and when the hole was full of cells, the cells were harvested and cultured in 48 wells, 24 wells, 12 wells and 6 well plates and T25 and T75 flasks. Finally, cells were cultured in T175 flasks to generate cell stocks.

[0093] 2-3. Confirmation of HLA-G expression in SK-OV-3 and MDA-MB-231 cell lines expressing B2M-HLA-G-EGFP-PuroR gene

[0094] The expression of HLA-G in the HLA-G overexpressing cell line generated in 2-2 above was confirmed as follows.

[0095] 1x10 of SK-OV-3 and MDA-MB-231 cell lines expressing B2M-HLA-G-EGFP-PuroR gene were cultured in 5Each cell was suspended in 100 μL of Dubeco's phosphate buffered saline (D-PBS) (Gibco, USA) to prepare a cell sample. 1 μg of anti-HLA-G (TANKIO17) antibody was added to the cell sample, and the cells were reacted at 4 ° C for 30 minutes. After the reaction was completed, the cells were washed twice with D-PBS and resuspended. 0.25 μg of R-phycoerythrin AffiniPure F (ab') 2 fragment goat anti-human IgG (H + L) (Jackson ImmunoResearch, USA) was added to the cell sample, and the cells were reacted at 4 ° C for 30 minutes. After the reaction, the cells were washed twice with D-PBS, and the expression of HLA-G was confirmed by flow cytometry. As a result, it was confirmed that approximately 99.8% of HLA-G was expressed on the surface of SK-OV-3 cells to which B2M-HLA-G-EGFP-PuroR lentivirus was delivered, and approximately 98.9% of HLA-G was expressed on the surface of MDA-MB-231 cells ( Figure 4 ).

[0096] Example 3: Construction of CAR

[0097] The CAR of the present invention is artificially synthesized.

[0098] More specifically, the following extracellular domain and intracellular domain coding sequences were artificially synthesized by overlap extension polymerase chain reaction (SOE-PCR) using splicing to produce CAR ( Figures 1a to 1c The PCR product was digested with MluI and XbaI and then inserted into the MluI and XbaI sites of the pLV-EF1A-MCS vector, which is a third-generation self-inactivating lentiviral expression vector ( Figures 2a to 2c ).

[0099] - Extracellular domains: CD8α-derived LS, HLA-G binding domain (antibody fragment 1, antibody fragment 2, or antibody fragment 3; scFv), CD8α-derived hinge, and CD8α-derived TM domain

[0100] - Intracellular domain: intracellular signaling domain of 4-1BB and CD3ζ

[0101] CAR according to an embodiment of the present invention is summarized in Table 1 below. The domains of CAR are connected in series with each other and are also in the frame. Specifically, CD8α-derived LS, HLA-G binding domain (in the form of scFv), CD8α-derived hinge, CD8α-derived TM domain, 4-1BB-derived intracellular signaling domain, CD3ζ-derived intracellular signaling domain and stop codon TAA are connected.

[0102] [Table 1]

[0103]

[0104] The sequence information of CAR according to an embodiment of the present invention and the domains used in its preparation are summarized in Tables 2 and 3.

[0105] [Table 2]

[0106]

[0107]

[0108] [Table 3]

[0109]

[0110]

[0111]

[0112]

[0113]

[0114]

[0115]

[0116]

[0117]

[0118]

[0119]

[0120] The sequence listings of the heavy chain, light chain and CDR of the antibody fragment variable region used to generate CAR according to the embodiments of the present invention are summarized in Tables 4 and 5.

[0121] [Table 4]

[0122]

[0123] [Table 5]

[0124]

[0125]

[0126] Example 4: Generation of anti-HLA-G CAR-T cells

[0127] 4-1. Production of lentivirus expressing anti-HLA-G CAR gene

[0128] Lentivirus for delivering anti-HLA-G CAR gene was generated by plasmid DNA transfection. TransIT-293 transfection reagent (Mirus Bio LLC, USA) was used and transfection was performed according to the manufacturer's protocol. Lenti-X TM 5×10 of 293T cell line (Clontech, USA) 6 Cells were seeded in 100 mm culture dishes and transfected with pLV-EF1A-HLA-G CAR lentiviral vector, gag-pol expression vector and VSV-G envelope expression vector on the second day. The HLA-G CAR lentiviral vectors were as follows; antibody fragment 1, antibody fragment 2 or antibody fragment 3. After transfection, the cells were cultured for approximately 72 hours, and all cell supernatants were harvested after the culture was completed. The supernatant was filtered through a 0.45 μm filter (Millipore, USA) to remove cell debris. Lenti-X was used according to the manufacturer's protocol. TM The lentivirus was concentrated approximately 100-fold using a ELISA concentrator (Clontech, USA) and stored frozen at -80°C until use.

[0129] 4-2. Generation and culture of T cells expressing anti-HLA-G CAR

[0130] Donors were recruited and white blood cells were obtained by leukapheresis. TM Peripheral blood mononuclear cells (PBMCs) were obtained from leukocytes using Ficoll-50 (STEMCELL Technology, Canada) and Ficoll-Paque PLUS (GE Healthcare, Sweden). TM Human T cells were isolated by positive selection using a TexMACS Separator (Miltenyi Biotec, Germany), large (LS) columns (Miltenyi Biotec, Germany), human CD4 microbeads (Miltenyi Biotec, Germany), and human CD8 microbeads (Miltenyi Biotec, Germany). TM Culture medium (Miltenyi Biotec, Germany) and supplemented with human T cell TransAct TM (Miltenyi Biotec, Germany) for activation. For the growth of T cells, human IL-2 (R&D Systems, USA) was added to the culture medium at 100 U / mL and cultured. After 48 hours of culture, the activated T cells were harvested and used for lentiviral transduction.

[0131] Activated human T cells were inoculated with lentivirus at a multiplicity of infection (MOI) of approximately 3 at 1 x 10 cells per well. 6 Place the cells at a density of 10 μg / mL in a 12-well plate and prepare the culture medium to a volume of 2.5 mL. Transduce the lentivirus into T cells by centrifugation at 1,000 x g for 15 minutes. After culturing the T cells for 48 hours by static culture, replace the culture medium with fresh culture medium. Transduced human T cells were cultured at 5x10 μL at intervals of two to three days. 5 / mL for subculture and maintenance so that the cell number does not exceed 2x10 6 Unless otherwise mentioned, human T cells were cultured by adding 100 U / mL of IL-2 (R&D Systems, USA) to the culture medium.

[0132] 4-3. Confirmation of CAR expression in T cells expressing anti-HLA-G CAR

[0133] It was confirmed whether the anti-HLA-G CAR was expressed on the cell surface of anti-HLA-G CAR-expressing T cells generated from leukocytes obtained from three donors.

[0134] Harvest 1x10 5 After 100 cells, the cells were suspended in 100 μL D-PBS to prepare a cell suspension. Phycoerythrin (PE) fluorescence was conjugated to the B2M-HLA-G antigen for producing anti-HLA-G antibodies using a PE conjugation kit (Abcam, USA). The B2M-HLA-G antigen-PE conjugate was added to the cell suspension and reacted at 4 ° C for 30 minutes. After the reaction was completed, the cells were washed twice with D-PBS, and the expression level of anti-HLA-G CAR was confirmed by flow cytometry.

[0135] As a result, in donor 1, approximately 34.9% of anti-HLA-G CAR was expressed on the surface of T cells into which the anti-HLA-G CAR (antibody fragment 1 CAR) gene was transduced, approximately 45.8% of anti-HLA-G CAR was expressed on the surface of T cells into which the anti-HLA-G CAR (antibody fragment 2 CAR) gene was transduced, and approximately 43.3% of anti-HLA-G CAR was expressed on the surface of T cells into which the anti-HLA-G CAR (antibody fragment 3 CAR) gene was transduced ( Figure 5a ).

[0136] As a result, in donor 2, approximately 37.6% of anti-HLA-G CAR was expressed on the surface of T cells into which the anti-HLA-G CAR (antibody fragment 1 CAR) gene was transduced, approximately 57.3% of anti-HLA-G CAR was expressed on the surface of T cells into which the anti-HLA-G CAR (antibody fragment 2 CAR) gene was transduced, and approximately 38.1% of anti-HLA-G CAR was expressed on the surface of T cells into which the anti-HLA-G CAR (antibody fragment 3 CAR) gene was transduced ( Figure 5b ).

[0137] As a result, in donor 5, approximately 30.4% of anti-HLA-G CAR was expressed on the surface of T cells into which the anti-HLA-G CAR (antibody fragment 1 CAR) gene was transduced, approximately 46.2% of anti-HLA-G CAR was expressed on the surface of T cells into which the anti-HLA-G CAR (antibody fragment 2 CAR) gene was transduced, and approximately 37.4% of anti-HLA-G CAR was expressed on the surface of T cells into which the anti-HLA-G CAR (antibody fragment 3 CAR) gene was transduced ( Figure 5c ).

[0138] Example 5: Confirmation of the in vitro anti-cancer efficacy of T cells expressing anti-HLA-G CAR

[0139] The anti-cancer efficacy of T cells (effector cells, E) expressing anti-HLA-G CAR against target cells (T) was confirmed by the following method.

[0140] (i) All target cells were prepared to overexpress EGFP.

[0141] (ii) Target cells were plated at 1 x 10 5 Cells / 150 μL were added to a 48-well plate.

[0142] (iii) 1x10 per well 6 cells / 150μL, 5x10 5 cells / 150 μL and 1x10 5 T cells expressing anti-HLA-G CAR and control T cells (E:T ratio = 10, 5, 1) were added to each 10 cells / 150 μL and allowed to react with target cells for 24 hours.

[0143] (iv) Since the EGFP fluorescence signal disappears when the target cells die, the number of cells expressing EGFP was counted using flow cytometry after 24 hours.

[0144] [Equation 1]

[0145] Cytotoxicity (%) = 100 - {(EGFP after co-culture of target cells and effector cells + Cell number / EGFP after culturing target cells alone + Number of cells) x 100}

[0146] As a result of the experiment, three types of T cells expressing anti-HLA-GCAR (antibody fragment 1CAR), anti-HLA-G CAR (antibody fragment 2CAR), and anti-HLA-G CAR (antibody fragment 3CAR) generated from leukocytes of donor 1 had significantly higher anti-cancer efficacy against the SK-OV-3-HLA-G cell line overexpressing HLA-G than control T cells that did not express anti-HLA-G CAR. However, there was no difference in the killing ability of the three types of T cells expressing anti-HLA-G CAR and control T cells against SK-OV-3 cells that did not express anti-HLA-G ( Figure 6a ).

[0147] The three types of T cells expressing anti-HLA-G CAR (antibody fragment 1 CAR), anti-HLA-G CAR (antibody fragment 2 CAR), and anti-HLA-G CAR (antibody fragment 3 CAR) generated by leukocytes of donor 2 had significantly higher anti-cancer efficacy against the MDA-MB-231-HLA-G cell line overexpressing HLA-G than the control T cells that did not express anti-HLA-G CAR. On the other hand, there was no difference in the killing ability of the three types of T cells expressing anti-HLA-G CAR and the control T cells against the MDA-MB-231 cell line that did not express anti-HLA-G ( Figure 6b ).

[0148] The three types of T cells expressing anti-HLA-G CAR (antibody fragment 1 CAR), anti-HLA-G CAR (antibody fragment 2 CAR), and anti-HLA-G CAR (antibody fragment 3 CAR) generated by leukocytes of donor 5 also had significantly higher anti-cancer efficacy against SK-OV-3-HLA-G and MDA-MB-231-HLA-G cell lines that overexpress HLA-G than control T cells that do not express anti-HLA-G CAR. However, there was no difference in the killing ability of the three types of T cells expressing anti-HLA-G CAR and control T cells against SK-OV-3 and MDA-MB-231 cell lines that do not express anti-HLA-G ( Figure 6c ).

[0149] The above results confirmed that T cells expressing anti-HLA-G CAR have high killing ability only specifically targeting cells that highly express HLA-G.

[0150] Cell supernatants were harvested from the experimental group in which T cells expressing anti-HLA-G CAR and control T cells generated from donor 5 were treated with target cells at an E:T ratio of 1: 1. Interferon gamma concentrations in the harvested supernatants were measured using a human IFN-γ Quantikine enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, USA).

[0151] As a result, it was confirmed that the secretion of interferon γ was significantly increased only when T cells expressing three types of anti-HLA-G CAR (antibody fragment 1 CAR), anti-HLA-G CAR (antibody fragment 2 CAR), and anti-HLA-G CAR (antibody fragment 3 CAR) were co-cultured with SK-OV-3-HLA-G or MDA-MB-231-HLA-G target cell lines overexpressing HLA-G ( Figure 7 ).

[0152] Example 6: Comparison of in vitro anticancer efficacy of T cells expressing anti-HLA-G CAR according to T cell culture conditions

[0153] T cells expressing anti-HLA-G CAR (antibody fragment 2 CAR) were produced in the manner mentioned in Example 4-2. At this time, for the growth of T cells, human IL-2 (R&D Systems, the United States) was added to the culture medium at 100 U / mL, or IL-7 (Miltenyi Biotec, Germany) and IL-15 (Miltenyi Biotec, Germany) were added at 12.5 ng / mL, and then the cells were cultured.

[0154] As a result of confirming whether anti-HLA-G CAR is expressed on the cell surface of anti-HLA-G CAR-expressing T cells, it was confirmed that approximately 48.3% of anti-HLA-G CAR was expressed on the surface of anti-HLA-G CAR-expressing T cells cultured by adding IL-2 to the medium, and approximately 47.9% of anti-HLA-G CAR was expressed on the surface of anti-HLA-G CAR-expressing T cells cultured by adding IL-7 and IL-15 to the medium ( Figure 8 ).

[0155] As a result of confirming the anti-cancer efficacy by co-culturing T cells expressing anti-HLA-G CAR with target cells, T cells expressing anti-HLA-G CAR (IL-2) and T cells expressing anti-HLA-G CAR (IL-7 / IL-15) were equally excellent in anti-cancer efficacy against the SK-OV-3-HLA-G cell line overexpressing HLA-G. On the other hand, the killing ability against the SK-OV-3 cell line that does not express HLA-G was significantly lower, so there was no difference in the killing ability of these two types of T cells expressing anti-HLA-G CAR ( Fig. 9 ).

[0156] Cell supernatants were harvested from the experimental group in which T cells expressing anti-HLA-G CAR were treated with target cells at an E:T ratio of 1:1, and the concentration of interferon γ was measured using a human IFN-γQuantikine ELISA kit (R&D Systems, USA). As a result, it was confirmed that the secretion of interferon γ was significantly increased only when T cells expressing anti-HLA-G CAR (IL-2) or T cells expressing anti-HLA-G CAR (IL-7 / IL-15) were co-cultured with the SK-OV-3-HLA-G target cell line overexpressing HLA-G, and there was almost no difference between these two types of T cells expressing anti-HLA-G CAR ( Fig.10 ).

[0157] Through the above results, it was confirmed that T cells expressing anti-HLA-G CAR showed similar CAR expression levels regardless of the type of cytokines added to the culture medium for T cell growth (IL-2 or IL-7 / IL-15), and both types of T cells expressing anti-HLA-G CAR showed good in vitro anticancer efficacy.

[0158] Example 7: Generation of anti-HLA-G CAR-NK cells and confirmation of anti-cancer efficacy

[0159] 7-1. Generation and culture of NK cells expressing anti-HLA-G CAR

[0160] Donors were recruited and white blood cells were obtained by leukapheresis. TM PBMCs were obtained from leukocytes using 1% paraformaldehyde (PAGE)-50 (STEMCELL Technology, Canada) and Ficoll-Paque PLUS (GE Healthcare, Sweden). Human NK cells were then isolated by negative selection using an NK cell isolation kit (Miltenyi Biotec, Germany). Human NK cells were cultured in 1% GemCell 500 (Miltenyi Biotec, Germany) medium. For the efficient growth of NK cells, 5% GemCell 500 (500 U / mL) and 140 U / mL were added to the culture medium. TM Human serum AB (GeminiBio, USA) and human IL-2 (R&D Systems, USA) and IL-15 (Miltenyi Biotec, Germany) were used to culture cells.

[0161] (Takara, Japan) and BX-795 (Sigma-Aldrich, USA) were used to efficiently deliver lentivirus into NK cells. The lentivirus with an MOI of approximately 10 was placed in a RetroNectin-coated 24-well plate and adsorbed according to the manufacturer's protocol. 5x10 5 NK cells were treated with 2.5 μM BX-795 for 30 minutes. Then, the NK cells treated with BX-795 were placed in a lentivirus adsorption plate and centrifuged at 1,000 x g for 15 minutes to deliver the lentivirus into the NK cells. Then, the NK cells were cultured for 24 hours by static culture, and then the culture medium was replaced with fresh culture medium. The transduced human NK cells were appropriately subcultured at intervals of three to four days.

[0162] 7-2. Confirmation of CAR expression in NK cells expressing anti-HLA-G CAR

[0163] First, we confirmed whether NK cells expressing anti-HLA-G CAR were cultured correctly. 5 Cells were collected and suspended in 100 μL D-PBS to prepare a cell suspension. VioBlue-conjugated CD3 antibody (Miltenyi Biotec, Germany) and FITC-conjugated CD56 antibody (Miltenyi Biotec, Germany) were added to the cell suspension and reacted at 4°C for 30 minutes. After the reaction, the cells were washed twice with D-PBS, and the expression levels of CD3 and CD56 were confirmed by flow cytometry.

[0164] As a result, it was found that CD3 - CD56 +The proportion of NK cells was 99.1% in the control NK cells, 99.1% in the NK cells into which the anti-HLA-G CAR (antibody fragment 1 CAR) gene was transduced, 98.9% in the NK cells into which the anti-HLA-G CAR (antibody fragment 2 CAR) gene was transduced, and 99.1% in the NK cells into which the anti-HLA-G CAR (antibody fragment 3 CAR) gene was transduced, confirming that almost all the cells were CD3 - CD56 + NK cells ( Fig.11 ).

[0165] Next, confirm whether the anti-HLA-G CAR is expressed on the surface of each cell. Harvest 1x10 5 Cells were added and suspended in 100 μL D-PBS to prepare a cell suspension. PE fluorescence was conjugated to the B2M-HLA-G antigen for producing anti-HLA-G antibodies using a PE conjugation kit (Abcam, USA). B2M-HLA-G antigen-PE conjugate was added to the cell suspension and reacted at 4 ° C for 30 minutes. After the reaction was completed, the cells were washed twice with D-PBS, and the expression of anti-HLA-G CAR was confirmed by flow cytometry.

[0166] As a result, it was confirmed that about 18.8% of the anti-HLA-G CAR was expressed on the surface of the NK cells into which the anti-HLA-G CAR (antibody fragment 1 CAR) gene was transduced, about 25.5% of the anti-HLA-G CAR was expressed on the surface of the NK cells into which the anti-HLA-G CAR (antibody fragment 2 CAR) gene was transduced, and about 22.4% of the anti-HLA-G CAR was expressed on the surface of the NK cells into which the anti-HLA-G CAR (antibody fragment 3 CAR) gene was transduced ( Fig.12 ).

[0167] 7-3. Confirmation of in vitro anticancer efficacy of NK cells expressing anti-HLA-G CAR

[0168] The anti-cancer efficacy of NK cells expressing anti-HLA-G CAR was confirmed in the same manner as in Example 5.

[0169] As a result, the three types of NK cells expressing anti-HLA-G CAR (antibody fragment 1CAR), anti-HLA-G CAR (antibody fragment 2CAR), and anti-HLA-G CAR (antibody fragment 3CAR) had significantly higher anti-cancer efficacy against the SK-OV-3-HLA-G cell line overexpressing HLA-G than the control NK cells that did not express anti-HLA-G CAR. However, in the SK-OV-3 cell line, there was no difference in the killing ability between NK cells expressing anti-HLA-G CAR and control NK cells ( Fig.13 ).

Claims

1. An anti-human leukocyte antigen-G (anti-HLA-G) chimeric antigen receptor (CAR), comprising: An antigen binding domain that specifically binds to HLA-G; transmembrane domain; and Intracellular signaling domain, Wherein the antigen binding domain that specifically binds to HLA-G comprises a sequence selected from the following: (a) a heavy chain variable region comprising a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO: 31, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 32, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 33; and a light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 34, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 35, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 36; (b) a heavy chain variable region comprising a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 37, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 38, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 39; and a light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO:40, a light chain CDR2 having the amino acid sequence of SEQ ID NO:41, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:42; or (c) a heavy chain variable region comprising a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 43, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 44, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 45; and A light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO:46, a light chain CDR2 having the amino acid sequence of SEQ ID NO:47, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:

48.

2. The anti-HLA-G CAR of claim 1, wherein the antigen binding domain that specifically binds to HLA-G is an antibody or an antigen binding fragment.

3. The anti-HLA-G CAR of claim 2, wherein the antigen binding fragment is a single-chain variable fragment (scFv).

4. The anti-HLA-G CAR of claim 1, wherein the CAR further comprises a leader sequence.

5. The anti-HLA-G CAR of claim 4, wherein the leader sequence is a leader sequence derived from cluster of differentiation 8 alpha (CD8α), human immunoglobulin heavy chain, or human granulocyte-macrophage colony stimulating factor (hGM-CSF) receptor α-chain.

6. The anti-HLA-G CAR of claim 5, wherein the CD8α-derived leader sequence comprises the amino acid sequence of SEQ ID NO:

8.

7. The anti-HLA-G CAR of claim 1, wherein the antigen binding domain that specifically binds to HLA-G is connected to the transmembrane domain via a hinge.

8. The anti-HLA-G CAR of claim 7, wherein the hinge is selected from the group consisting of a hinge of CD8α, a hinge of IgG1, a hinge of IgG4, a hinge of IgD, IgG1 CH3, an extracellular domain of CD28, or a combination thereof.

9. The anti-HLA-G CAR of claim 8, wherein the hinge of the CD8α comprises the amino acid sequence of SEQ ID NO:

10.

10. The anti-HLA-G CAR of claim 1, wherein the transmembrane domain is a transmembrane domain of a protein selected from the group consisting of CD8α, T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD99, CD134, CD137, and alpha (α), beta (β), or zeta (ζ) of CD154.

11. The anti-HLA-G CAR of claim 10, wherein the transmembrane domain of CD8α comprises the amino acid sequence of SEQ ID NO:

12.

12. The anti-HLA-G CAR of claim 1, wherein the intracellular signaling domain is derived from a protein selected from the group consisting of CD3ζ, Fcγ receptor (FcγR), inducible T cell co-stimulator (ICOS; CD278), 4-1BB (CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9)), OX40 (CD134), CD27, CD28, interleukin-2 receptor β (IL-2Rβ), IL-15R-α, CD40, myeloid differentiation primary response 88 (MyD88), DNAX activating protein 10 (DAP10), DAP12, major histocompatibility complex (MHC) class I molecules, tumor necrosis factor (TNFRSF9), OX40 (CD134), CD27, CD28, interleukin-2 receptor β (IL-2Rβ), IL-15R-α, CD40, myeloid differentiation primary response 88 (MyD88), DNAX activating protein 10 (DAP10), DAP12, major histocompatibility complex (MHC) class I molecules, tumor necrosis factor (TNF F) receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte activation molecule (SLAM) proteins, activated NK cell receptors, B and T lymphocyte attenuation factor (BTLA), toll-like receptors (TLR), CD2, CD7, CD30, CD99, CDS, intercellular adhesion molecule-1 (ICAM-1), B7-H3 (CD276), glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR), B cell activating factor (BAFF) receptor (BAFFR), lymphotoxin-β receptor interacting cytokine (LIGHT), herpes virus entry mediator (HVEM) (LI GHT receptor (LIGHTR)), killer cell immunoglobulin-like receptor two Ig domains and short cytoplasmic tail 2 (KIRDS2), signaling lymphocyte activation molecule (SLAM) family member 7 (SLAMF7), NKp80 (killer cell lectin-like receptor subfamily F member 1 (KLRF1)), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL2Rγ, IL7Rα, integrin subunit α4 (ITGA4), very late antigen-1 (VLA1), CD49a, IA4, CD49D, integrin subunit α6 (ITGA6), VLA-6, CD49f, integrin subunit αD (ITGAD), CD11d, integrin subunit αE (ITGAE), CD103, integrin subunit αL (ITGAL), CD11a, lymphocyte function-associated antigen-1 (LFA-1; CD11a / CD18), integrin subunit αM (ITGAM), CD11b, integrin subunit αX (ITGAX), CD11c, integrin β-1 (ITGB1), CD29, integrin β-2 (ITGB2), CD18, integrin β-7 (ITGB7), natural killer group 2 member D (NKG2D; killer cell lectin-like receptor K1 (KLRK1)), natural killer group 2 member C (NKG2C;(Killer cell lectin-like receptor C2 (KLRC2)), tumor necrosis factor receptor 2 (TNFR2), TNF-related activation-inducing cytokine (TRANCE; nuclear factor κB receptor activator ligand (RANKL)), DNAX accessory molecule-1 (DNAM1; CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Touch), carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), cytotoxic and regulatory T cell molecule (CRTAM), Ly9 (CD229), CD160 (BY55), P-selectin glycoprotein ligand 1 (PSGL1; CD162), CD100 (semaphorin 4D (SEMA4D), CD69, SLAMF6 (NK-TB antigen (NTB-A)), Ly108, SLAMF1 (CD150, IPO-3), B lymphocyte activation regulator and enhancer (BLAME; SLAMF8), lymphotoxin-β receptor (LTBR), T cell activation adaptor (LAT), glutamic acid decarboxylase (GADS), 76-kDa leukocyte phosphoprotein containing Src sequence homology 2 (SH2) domain (SLP-76), phosphoprotein associated with glycosphingolipid-rich microdomain / C-terminal Src kinase (Csk) binding protein (PAG / Cbp), CD19a and CD83 specific ligands. ; 13. The anti-HLA-G CAR of claim 12, wherein the CD3ζ-derived intracellular signaling domain comprises the amino acid sequence of SEQ ID NO:

16.

14. The anti-HLA-G CAR of claim 1, wherein the intracellular signaling domain further comprises a co-stimulatory domain derived from a protein selected from the group consisting of: OX40, CD2, CD27, CD28, CD99, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), and 4-1BB (CD137).

15. The anti-HLA-G CAR of claim 14, wherein the 4-1BB-derived co-stimulatory domain comprises the amino acid sequence of SEQ ID NO:

14.

16. An isolated nucleic acid comprising a nucleotide sequence encoding the anti-HLA-G CAR of any one of claims 1 to 15.

17. A vector comprising the isolated nucleic acid of claim 16.

18. An immune cell expressing the anti-HLA-G CAR according to any one of claims 1 to 15 on its surface.

19. The immune cell of claim 18, wherein the immune cell is selected from the group consisting of natural killer cells, T cells, natural killer T cells, B cells, macrophages, dendritic cells, natural killer dendritic cells, mast cells, and precursor cells thereof.

20. A pharmaceutical composition for preventing or treating cancer, comprising the immune cell according to claim 18 or claim 19 and a pharmaceutically acceptable carrier.

21. The pharmaceutical composition of claim 20, wherein the cancer is selected from the group consisting of pancreatic cancer, breast cancer, ovarian cancer, glioma, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, liver cancer, lung cancer, colon cancer, nasopharyngeal cancer, oral cancer, thyroid cancer, prostate cancer, kidney cancer, gallbladder cancer, bile duct cancer, blood cancer, and melanoma.

22. A method for preventing or treating cancer, comprising administering the immune cell of claim 18 or claim 19 or the pharmaceutical composition of claim 20 to a subject in need thereof.